MedPath

Bioxytran's Preprint Highlights Galectin-3 Modulation as Key to Enhancing Immunotherapy Efficacy

7 months ago2 min read

Bioxytran's Groundbreaking Research on Immunotherapy Enhancement

Bioxytran, Inc., a clinical-stage biotechnology company, has recently published a preprint article that could mark a significant advancement in cancer treatment. The article, titled "Immune Checkpoint Inhibitors (ICI): Prospects for Galectin-3 Modulation to Increase Objective Response Rate (ORR) and Remission-free Survival in Oncology Patients," delves into the mechanisms behind resistance to ICI therapy and the pivotal role of galectin-3 in this process.

The Role of Galectin-3 in Cancer Treatment Resistance

Galectin-3 has been identified as a critical factor in the resistance to ICI therapy, particularly in Non-Small Cell Lung Cancer (NSCLC). The research highlights that 90% of NSCLC patients with high levels of galectin-3 did not experience tumor shrinkage after three ICI treatments. Conversely, patients with low to moderate galectin-3 expression showed a positive response to ICI therapy, suggesting that galectin-3 levels could serve as a predictive biomarker for ICI efficacy.

Overcoming Resistance with Galectin-3 Antagonists

The preprint also explores the mechanism by which galectin-3 contributes to ICI resistance. Through advanced techniques like Surface Plasmon Resonance and cryogenic electron microscopy, researchers discovered that galectin-3 binds to the PD-1 receptor, preventing ICIs from attaching and thereby allowing PD-L1 to bind and deactivate T-cells. This discovery opens the door to potential treatments using galectin-3 antagonists to reverse this effect and enhance the efficacy of ICI therapy.

A New Paradigm in Cancer Treatment

Dr. David Platt, CEO of Bioxytran, emphasized the significance of these findings, stating, "Our findings herald a significant shift in cancer treatment paradigms." The research not only sheds light on the variable responses to immunotherapy but also identifies galectin-3 as a key driver of disease progression and resistance. The potential of combining galectin-3 antagonists with existing cancer treatments could significantly improve patient outcomes.

Looking Ahead

Bioxytran's research is part of a broader effort to address the challenges in cancer treatment, particularly the mechanisms by which cancer evades the immune system. The company's focus on galectin antagonists represents a promising avenue for enhancing the effectiveness of immunotherapy and improving the lives of cancer patients worldwide.
For more information on Bioxytran's research and development efforts, visit www.bioxytraninc.com.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.